AstraZeneca announces that a phase III trial showed that Imfinzi (durvalumab) in combination with chemotherapy, demonstrated a statistically and clinically significant improvement in event-free survival and overall survival compared to neoadjuvant chemotherapy, in patients with muscle-invasive bladder cancer (MIBC).

Patients were treated with Imfinzi in combination with neoadjuvant chemotherapy prior to cystectomy (surgery to remove the bladder), followed by Imfinzi as adjuvant monotherapy.

Approximately one in four bladder cancer patients has evidence of tumor invasion of the bladder muscle wall (without distant metastases), known as MIBC.

These data show for the first time that adding durvalumab to chemotherapy before surgery, followed by durvalumab, prolongs patients' lives", said Professor Thomas Powles, Professor and Director of Barts Cancer Centre (QMUL), London.

Copyright (c) 2024 CercleFinance.com. All rights reserved.